Poseida Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Poseida Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.3%
Buyback Yield
| Total Shareholder Yield | -0.3% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities
Nov 26Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Oct 19
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Sep 30Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PSTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PSTX's dividend payments have been increasing.
Dividend Yield vs Market
| Poseida Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PSTX) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (PSTX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate PSTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PSTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PSTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PSTX has not reported any payouts.